metaPreg - Atenolol (versus unexposed) during pregnancy

Atenolol (versus unexposed) updated on 12-17-2024

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	2.78 [2.23, 3.46]	3%	8 studies	49,345	1,038	serious	ROB	5.00 [3.89; .]
Low birth weight (< 2500g)	4.01 [3.33, 4.83]	0%	3 studies	29,549	746	not evaluable	ROB	7.48 [6.11; .]
Preterm (< 37 weeks)	2.70 [1.75, 4.17]	0%	2 studies	7,894	185	not evaluable	ROB	4.85 [2.91; .]
Very low birth weight (< 1500g)	4.21 [2.80, 6.34]	-	1 study	3,465	638	not evaluable	ROB	7.89 [5.04; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	2.10 [0.64, 6.88]	91%	4 studies	3,543	863	not evaluable	ROB	-
Caesarean	2.48 [2.13, 2.88]	0%	3 studies	104,581	756	not evaluable	ROB	4.39 [3.67; .]
Assisted deliveries (forceps, vacuum, ...)	1.38 [0.89, 2.12]	0%	2 studies	8,259	678	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low Apgar score (< 7) (at 1 min)	2.02 [1.43, 2.84]	21%	3 studies	22,618	785	not evaluable	ROB	3.45 [2.22; .]
Low Apgar score (< 7) (at 5 min)	1.75 [0.53, 5.79]	23%	3 studies	4,064	785	not evaluable	ROB	-
Neonatal hypoglycemia	2.22 [0.80, 6.15]	58%	2 studies	119	1,161	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study